Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.270
+0.040 (3.25%)
At close: Oct 13, 2025, 4:00 PM EDT
1.260
-0.010 (-0.79%)
After-hours: Oct 13, 2025, 6:33 PM EDT
Allogene Therapeutics Stock Forecast
ALLO's stock price has decreased by -52.08% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 10 analysts that cover Allogene Therapeutics stock have a consensus rating of "Buy" and an average price target of $8.80, which forecasts a 592.91% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $14.
Price Target: $8.80 (+592.91%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 1, 2025.
Analyst Ratings
The average analyst rating for Allogene Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 7 | 7 | 7 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Oct 10, 2025 |
| JMP Securities | JMP Securities | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 4, 2025 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Aug 4, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $9 → $7 | Buy | Maintains | $9 → $7 | +451.18% | Aug 1, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +214.96% | May 15, 2025 |
Financial Forecast
Revenue This Year
10.20K
from 22.00K
Decreased by -53.64%
Revenue Next Year
20.40K
from 10.20K
Increased by 100.00%
EPS This Year
-1.00
from -1.32
EPS Next Year
-0.94
from -1.00
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 105,000 | 105,000 | |||
| Avg | 10,200 | 20,400 | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 377.3% | 929.4% | |||
| Avg | -53.6% | 100.0% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.92 | -0.58 | |||
| Avg | -1.00 | -0.94 | |||
| Low | -1.18 | -1.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.